Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

White Paper

Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

This paper explores the reason behind this about-face, potential policy alternatives President Trump may pursue to reduce drug prices and their adverse consequences, and what shoul ...

PBMs Pharma Benefit Manager

White Paper

Proposed Rule To End Rebates To PBMs For Medicare And Medicaid Programs

This white paper looks at how rebates to PBMs relate to drug prices from two perspectives: how they are supposed to work versus what actually happens. ...

Growing Attention Being Paid To Pharma Company Rebates And Discounts

White Paper

Growing Attention Being Paid To Pharma Company Rebates And Discounts

Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...

Perspectives On Pharma Company Use Of Open Payments Data

White Paper

Perspectives On Pharma Company Use Of Open Payments Data

This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...

Pricing and Market Effects of Biosimilar Entry in the US

White Paper

Pricing and Market Effects of Biosimilar Entry in the US

This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...

Make US Pharma Great Again!? - Part 1

White Paper

Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies

President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...

Econometric Analysis Of Biopharmaceutical Transfer Pricing

White Paper

Econometric Analysis Of Biopharmaceutical Transfer Pricing

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of ...

The Relationship Between Drug Price Controls And Patient Health Outcomes

White Paper

The Relationship Between Drug Price Controls And Patient Health Outcomes

No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service r ...

The Pricing Challenge Of Pharma's Shift To Specialty Medicines

White Paper

The Pricing Challenge Of Pharma’s Shift To Specialty Medicines

The shift to specialty medicines has opened up for pharma companies a wealth of opportunities in addressing unmet medical needs of patients and improve the cost of care. This shift ...